The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction

被引:49
作者
Kuo, PL
Hsu, YL
Kuo, YC
Chang, CH
Lin, CC
机构
[1] Kaohsiung Med Univ, Coll Pharm, Grad Inst Nat Prod, Kaohsiung 807, Taiwan
[2] Chai Nan Univ Pharm & Sci, Dept Biotechnol, Tainan, Taiwan
[3] Chai Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan
关键词
apoptosis; Bax; Bcl-2; Bcl-X-L; cell cycle; ellipticine;
D O I
10.1097/01.cad.0000171768.36317.93
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ellipticine, a cytotoxic plant alkaloid, is known to inhibit topoisomerase II. Here we report the mechanism of apoptosis induction and cell cycle arrest by ellipticine in human breast MDA-MB-231 cancer cells. Ellipticine treatment arrested MDA-MB-231 cells at the G(2)/M phase after 6 h of treatment. This effect was strongly associated with a concomitant decrease in the level of cyclin 131, Cdc25 and Cdc2, and increase in phospho-Cdc2 (Tyr15). In addition, ellipticine also induced apoptosis in MDA-MB-231 cells, as determined by using both DNA fragmentation and Annexin-V staining assay. Ellipticine increased the expression of Bax, but decreased the level of Bcl-2, Bcl-X-L and X-linked inhibitor of apoptosis protein (XIAP), and subsequently triggered the mitochondrial apoptotic pathway (release of cytochrome c, and activation of caspase-9 and -3). In addition, pre-treatment of cells with caspase-9 inhibitor inhibited ellipticine-induced cell proliferation and apoptosis, indicating that caspase-9 activation was involved in MDA-MB-231 cell apoptosis induced by ellipticine. Taken together, our study suggests that the inhibition of cell cycle progression signaling xand initiation of the mitochondrial apoptotic system may participate in the anti-proliferative activity of ellipticine in MDA-MB-231 cells.
引用
收藏
页码:789 / 795
页数:7
相关论文
共 15 条
[1]   DESIGN, SYNTHESIS, AND STUDY OF 9-SUBSTITUTED ELLIPTICINE AND 2-METHYLELLIPTICINIUM ANALOGS AS POTENTIAL CNS-SELECTIVE ANTITUMOR AGENTS [J].
ANDERSON, WK ;
GOPALSAMY, A ;
REDDY, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (13) :1955-1963
[2]   Centrosomal and cytoplasmic cdc2/cyclin B1 activation precedes nuclear mitotic events [J].
De Souza, CPC ;
Ellem, KAO ;
Gabrielli, BG .
EXPERIMENTAL CELL RESEARCH, 2000, 257 (01) :11-21
[3]   Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates [J].
Devraj, R ;
Barrett, JF ;
Fernandez, JA ;
Katzenellenbogen, JA ;
Cushman, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) :3367-3374
[4]   Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells [J].
Di Gennaro, E ;
Barbarino, M ;
Bruzzese, F ;
De Lorenzo, S ;
Caraglia, M ;
Abbruzzese, A ;
Avallone, A ;
Comella, P ;
Caponigro, F ;
Pepe, S ;
Budillon, A .
JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 195 (01) :139-150
[5]  
DJURIC Z, 1992, CANCER RES, V52, P1515
[6]  
Frey MR, 1997, J BIOL CHEM, V272, P9424
[7]   ALKALOIDS OF OCHROSIA-ELLIPTICA LABILL [J].
GOODWIN, S ;
SMITH, AF ;
HORNING, EC .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1959, 81 (08) :1903-1908
[8]  
Hägg M, 2004, MOL CANCER THER, V3, P489
[9]   Multiple cell death pathways as regulators of tumour initiation and progression [J].
Jäättelä, M .
ONCOGENE, 2004, 23 (16) :2746-2756
[10]   PHASE-I STUDY OF RETELLIPTINE DIHYDROCHLORIDE (SR-95325-B) USING A SINGLE 2-HOUR INTRAVENOUS-INFUSION SCHEDULE [J].
KATTAN, J ;
DURAND, M ;
DROZ, JP ;
MAHJOUBI, M ;
MARINO, JP ;
AZAB, M .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (03) :242-245